The purpose of this study is to evaluate whether radiosurgery, along with standard chemotherapy, immunotherapy (the treatment of cancer by modulating the immune system and immune response), or hormonal therapy, affects the quality and length of life. The standard therapy is surgery, radiation therapy, or chemotherapy alone or in any combination. A second purpose of this study is to determine if the levels of a special type of protein (called cytokines) found in the blood are related to the quality of life while on this treatment.
Before treatment begins, you will have a physical exam and blood tests. Physical evaluations and blood tests will be done each week while you are receiving treatment, and at follow-up visits. You will be seen for follow-up evaluations 4 weeks after treatment is completed, and every three months thereafter. You will be asked to fill out a Quality of Life questionnaire, which should take 5-10 minutes to complete. This will be done prior to treatment and at your follow-up visits. You will receive high dose radiation therapy directed at the site of metastasis. This treatment will be given once a day, 5 times a week (Monday through Friday) for one to four weeks depending on the location and size of the disease to be treated.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
49
Hypofractionated Stereotactic Body Radiation Therapy
Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
Department of Radiation Oncology: University of Rochester
Rochester, New York, United States
Overall Survival
The percent of patients that survived from date of enrollment until 2 year follow-up visit.
Time frame: 2 years
Overall Survival
The percent of patients that survived from date of enrollment until 4 year follow-up visit
Time frame: 4 years
Overall Survival
The percent of patients that survived from date of enrollment until 6 year follow-up visit
Time frame: 6 years
Percent of Patients With Lesion Local Control
Lesion local failure was scored as an event if any treated lesion increased by greater than or equal to 20% using the Response Evaluation Criteria in Solid Tumors criteria or local failure was confirmed pathologically. Lesion control includes all participants that did not fall into the category of lesion failure.
Time frame: 6 years
Number of Participants Who Experienced a Grade 4 or 5 Toxicity
Number of participants who experienced a grade 4 or 5 toxicity
Time frame: 6 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.